CD274 and neoplasm: These results indicated that tumour antigen‐stimulated LAMP3_DC may augment anti‐PD‐L1 immune therapy activities in osteosarcoma patients and may serve as a potential biomarker to identify patients who are sensitive to PD‐L1 targeting treatments.